, Paris, France, assembled more than 250 participants representing research organizations from 26 countries. The symposium included a roundtable discussion on critical needs, challenges and opportunities, and a forward look at the potential applications of animal genomics in animal health research. The aim of the roundtable discussion was to foster a dialogue between scientists working at the cutting edge of animal genomics research and animal health scientists. In an effort to broaden the perspective of the roundtable discussion, the organizers set out four priority areas to advance the use of genome-enabled technologies in animal health research. Contributions were obtained through open discussions and a questionnaire distributed at the start of the symposium. This symposium report provides detailed summaries of the outcome of the roundtable discussion for each of the four priority areas. For each priority, the problems needing to be solved, according to the views of the participants, are identified, including potential solutions, recommendations, and lastly, concrete steps that could be taken to address these problems. This report serves as a roadmap to steer research priorities in animal genomics research.
INTRODUCTION
One of the primary aims of the International Symposium on Animal Genomics for Animal Health (AGAH) was to identify opportunities for integrating genomeenabled technologies in animal health research. To achieve this aim, a roundtable discussion ofleading experts in the field ofgenornics and animal health was organized. With contributions from the symposium participants, open discussions and a questionnaire distributed at the start of the symposium, four priorities were identified that are likely to have the greatest impact on animal genomics research:
I Quantitative genetic studies to identify markers of health traits 2 Functional genomics studies to understand host-pathogen interactions 3. Translating genomic information to tools for controlling diseases 4. Integrating stakeholder support to advance animal genomics in animal health This report captures the problems to be solved within the four priority areas and provides potential solutions, recommendations, and the next steps for moving forward.
FOUR PRIORITIES FOR ANIMAL GENOMICS RESEARCH

Quantitative genetic studies to identify markers of health traits
Genetic studies which aim to quantify between-host variation in health-related traits or intend to identify genetic markers associated with health have the potential to impact many areas of disease control. However, the interpretation of genetic studies has often highlighted the different perspectives held by the veterinary and animal genetics communities. For example, many in the veterinary medical field have viewed quantitative genetics as a means to emulate the success of the biomedical research community in identifying 'candidate genes'responsible for specific diseases. However, successes with livestock and poultry diseases have been relatively rare. Conversely, livestock and poultry production scientists have viewed quantitative genetics as a means of identifying diseases for which control strategies exploiting host genetics are feasible, possibly through marker-assisted selection of animals with desirable health traits. However, quantitative genetic studies to identify heritable health traits have notoriously been difficult and often remain unrealized; although successes have been achieved for some endemic diseases, genetically improving animal health remains a challenge.
One of the outcomes of the AGAH symposium is the realization that there are no generic solutions for solving the problems associated with quantitative genetic studies. However, the rapid and sustained development ofgenome-enabled technologies of the last few years provides extraordinary opportunities for advancing this field of research. One of the first and most exciting options to explore is the possibility of using dense single nucleotide polymorphism (SNP) maps coupled with haplotype information. Still, participants overwhelmingly agreed that the key challenge remains the lack ofvalidated animal phenotypes. Critical needs include standardized protocols for collecting tissues and phenotypes for disease resistance traits in both experimental resource and relevant commercial animal populations. Several participants recommended taking a 'big picture' view of the problems and suggested that it may be more productive to study many diseases in the same population than to conduct many smaller, 'more focused' disease-specific studies, as very large populations are required to obtain sufficient information for meaningful genetic analysis.
The main issues: -Availability and acquisition of appropriate and reliable health records -Availability and acquisition of animal pedigrees with defined phenotypes -Development and availability of genome-associated research tools -Refining quantitative population genetic studies to usable markers Availability and acquisition of appropriate and reliable health records a. Problem: The rate limiting step in studies aiming to detect genetic markers for health is invariably the collection of phenotypes, rather than genotypes. This is a general problem in many genomic studies, including studies on non-disease traits, and it is known generically as the 'phenotype gap.' However, the situation is exacerbated for disease traits as phenotypes of disease susceptibility/resistance to infectious diseases are often more difficult and/or expensive to measure than those for performance traits. Their measurement usually requires the involvement of infection (either deliberate or through clinical history of naturally infected animals).
There are many issues to be addressed in the definition and recording of health traits, and these issues should be the subject of debate between specialists with different areas of expertise. Each infectious disease will have its own unique solution, and whilst attempts should be made to capture as much information as possible in resource populations, practical considerations will more likely lead to the selection of animals with targeted disease or health-related traits.
Some diseases are multifactorial. For example, mastitis may be caused by many pathogens (e.g. Escherichia coli, Staphylococcus aureus, Mycoplasma bovis, Streptococcus uberis, Streptococcus agalactiae etc), and the pathogenesis resulting from these specific infections may differ dramatically. Therefore, an important issue is whether with these different forms of the disease it is possible to have generic solutions to the disease or, conversely, pathogen-specific solutions are required invoking considerable complexity in data recording. In many cases, disease outcomes may be the result of infection coinciding with stress induced immune suppression in livestock. An example is the respiratory diseases of livestock and poultry in intensive animal production systems caused by several different pathogens (viral and/or bacterial) in association with transport, comingling of pooled animals, dietary changes and administration of various veterinary treatments. Mastitis is another example of a disease where clinical cases often have an underlying issue of immune suppression in early lactation. In such cases, addressing animals' ability to cope with stress may be as effective as concentrating on animals' resistance to infection.
b. Potential Solutions:
As highlighted by many contributors, solutions and recommendations invariably involve large scale, multidisciplinary, sometimes multinational, projects which 'think big', i.e., maximize the use of animal resources and human expertise. In particular, it is critical that dialogue is established or strengthened between contributors with complementary expertise in animal health, animal genetics/genomicS and other relevant disciplines.
Animal health experts should also be aware that opportunities to record phenotypes may occur in populations that are not standard commercial populations or wellcharacterized experimental lines. For example, livestock exposed to extremes of environment or disease may be a rich reservoir of traits and genes related to health issues.
In general terms, the solutions must be tailored to the problem, and avoid wasted effort if host genetic studies are not appropriate. Several different situations can be envisaged. Consider the following scenarios:
• For predictable widespread diseases such as nematodiasis, mastitis, PRRS, PMWS and PCVAD -simple standardized measurement protocols are required that describe relative levels of infection or impact on the animals. • For emerging diseases such as bovine tuberculosis, bluetongue, aquaculture viral diseases -data capture from herds/flocks where disease outbreak has occurred is required. Recording ofcases and unaffected (or uninfected) 'controls', along with DNA capture will enable genome scans to be performed efficiently to address the question of host genetic control • Since data from disease outbreaks may be influenced by environmental factors, another approach to consider is the collection of data from challenge studies in a controlled laboratory setting to increase the power of detecting genetic factors involved in disease resistance phenotypes, provided that data on sufficient animals can be measured. It is advantageous to use the phenotypes of disease resistance to discover markers which are defined at the molecular level -these can then be used to enable selection to be performed on non-infected animals.
• For general health issues, e.g., when performance in commercial herds is lower than expected, or when general health issues are observed such as high incidence of respiratory diseases, optimal solutions have not yet been defined. Possibilities include detailed recording of specific health disorders, recording breedinganimal performance in environments that replicate commercial conditions, the use of immune measures to assess im munoresponsjveness or diagnose infection. From a purely genetics point of view, general health issues are more important than disease resistance to a specific disease because pathogens can evolve much faster than animal populations; therefore, genetic improvement in general health may be more sustainable.
• The option ofselectmg livestock with superior resistance to the immunosuppressive effects of stress should be explored. This may have applications for many livestock and poultry species, and potentially impact on common diseases such as respiratory diseases (e.g., the bovine respiratory disease complex), reproductive diseases (e.g., retained placenta & metritis) and enteric diseases.
c. Recommendations:
The goal should be to move toward more 'proactive' sample collection, with specific recommendations on optimum timing and handling of blood (or other tissue) sample collection for a wide array of immunological and other disease-related studies. Development of high-throughput technologies to evaluate the disease status of individuals in large populations would also be advantageous.
The following scenarios can be envisaged: • For predictable widespread diseases, international agreement is required for measurement protocols for predictable diseases. Extensive data needs to be collected and stored on accessible databases. • For emerging diseases, dialogue with governmental and other animal health policy makers is needed to ensure timely capture of epidemic outcome data, for use in population-level quantitative genetic or epidemiological analyses. • For general health issues, arguably, the best practice has not yet been defined.
Large-scale research into the best means of describing host genetic effects is required. Support research to define heath traits at the molecular level are needed. Narrowly defined phenotypes can significantly increase the power of detecting genetic factors involved in disease susceptibility and disease resistance.
• Include the collection of data on health traits in animal disease studies conducted in controlled laboratory settings to avoid the complication of associated environmental factors.
• Research into the identification of animals with superior ability to withstand the immunosuppressive effects of stress may open new opportunities.
d. Next Steps:
International-level dialogue is needed between geneticists, animal health experts and government policy makers, aiming to:
1. Define critical disease and health issues at the sector level; 2. Address technical problems of data capture; 3. Address funding of basic research to understand health traits at the molecular level; 4. Support collaborations between research centres with large resource populations and laboratories with capabilities to collect health-related phenotypes from appropriate samples; 5. Establish livestock DNA banks for use by the International Community to enable future opportunities. Wherever possible, utilizable samples (e.g. semen) should be retained from all animals in structured breeding programmes, irrespective of their genotype, for traits currently under selection.
Availability of animal pedigrees (on animals with detailed health records)
a. Problem: Quantitative genetic studies require knowledge of animal pedigrees relating to animals upon which selection is performed.
b. Potential Solutions: Vertical integration seen with pigs, poultry and aquaculture, reduces the unit cost of pedigree recording; however, in many situations, large-scale vertical integration is not feasible (e.g. dairy cattle, and most beef and sheep enterprises). Markerpanels, particularly dense SNP chips, offer a possibility to reconstruct pedigree relationships in cases where they are unknown, and also the possibility to improve pedigree descriptions (i.e., to get actual rather than average genetic relationships) in cases where pedigree is recorded. Another attractive solution that eliminates the need for animal pedigrees is to conduct genomc-wide association studies that use high density SNP chips, in which predictions of animals' genetic merit can be made independent of pedigrees.
c. Recommendations:
• Where possible, encourage the recording of animal pedigrees, particularly in industry-wide schemes targeted at recording animal health attributes.
• In all disease recording schemes retain tissue, a blood sample or a blood spot for future use -resultant DNA can be used for pedigree reconstruction as well as marker detection.
• Develop inter-operable databases for large-scale storage ofpedigree information, phenotypes, and associated environmental factors.
d. Next Steps:
1. Encourage dialogue between geneticists, animal breeding companies, animal health experts and policy makers, and epidemiologists to ensure maximum pedigree recording, or collection of samples from which DNA can be extracted. 2. Develop user-friendly tools to reconstruct pedigrees from marker data. 3. Support meetings and workshops to enhance communication and facilitate collaborations between quantitative geneticists and experts in animal health.
Development and availability of genome-associated research tools
a. Problem: Dense SNP chips (tens or hundreds of thousands of SNPs) are the key to effective and portable genetic marker studies. Currently these are costly and only truly available in species with a genome sequence (e.g., man, mouse, chicken). Another significant issue with animal genome sequences is the lack of annotation, which is mostly based on homology to genes in other animal species and not actual experimental testing in the species of interest. b. Potential Solution: Genome sequences are needed for all major livestock species and discovery of hundreds of thousands of validated SNPs. Also consider other high throughput technologies that measure RNA (DNA chips), protein (protein arrays or mass spectrometry), and metabolites. c. Recommendations: Continue and increase efforts in genome sequencing and SNP discovery. The formation of large international consortia is required to reduce the per-unit cost of using SNP chips. Also, support other high throughput technologies such as DNA chips and protein arrays. Refining quantitative population genetic studies to usable markers a. Problem: The step from discovery of significant marker associations to utilizable markers for animal health is long, difficult and expensive.
b. Potential Solutions: There are at least three potential scenarios:
• In some situations, where you have a readily measurable phenotype, it is not necessary to resolve the genetic marker to a causative mutation or tightly linked marker -in this case 'genome-wide selection' can be used. The sum of all SNP effects across the genome can be used to predict next generation performance/ resistance/health status. Where phenotypes are difficult to capture, or few/single genes dominate host genetic variation, a usable marker must be found. An SNP-based genome scan alone is unlikely to be sufficient, and information must be used from other sources ('screening filters'), including comparative genomics, functional genomic studies and verification in independent animals. Once a region on the genome is found, you should (1) refine the position using many more markers, (2) confirm the association, and (3) when possible, sequence as many animals as possible for novel genetic variants.
c. Recommendations:
• The development and demonstration of tools for genome wide selection is needed, as well as the capture of data (e.g., from endemic diseases) and DNA for use in such studies.
• Large-scale coordinated research programmes aimed at elucidating relevant aspects of host-pathogen interactions for high profile disease (e.g. FMD, CSF, PRRS, bovine tuberculosis, mastitis, coccidiosis, salmonella, Marek's disease, etc) are needed.
• Develop and integrate bioinformatics infrastructures in animal health research institutions.
• Develop statistical models and software to assess marker association studies.
d. Next Steps:
I. Build capacity by establishing international cooperations in host genomic studies, host-pathogen interactions and development ofanalyticallbioiflforflrlatic approaches and tools. 2. Develop an international working group of experts to assess and develop statistical models and software.
Functional genomics to understand host-pathogen interactions
New research strategies employing high-throughput gene expression analysis are providing novel platforms for more comprehensive understanding of hostpathogen interactions. In particular, functional genomics is rapidly revolutionizing the analysis of whole genome responses of the host to environmental, nutritional, or disease factors that affect the health of animals. The symposium included several presentations on gene expression and functional genomics studies that had the aim of looking for genes that were both differentially expressed and located within a QTL region. Several of the comments reflected the importance of basic research and the inclusion of genome-enabled technologies. Many of the questions and comments from the audience pointed out that the causative polymorphisms may reside on completely different chromosomes from the genes that are differentially expressed and the importance of considering epigenetic effects.
The main issues: 1. Availability of validated animal disease models 2. Animals with defined disease susceptible/disease resistant phenotypes 3. Bioinformatjcs tools 4. Identification of genes that are involved in the activation/repression of key regulatory pathways 5. Development and availability of reagents to study gene function 6. Discovery of biomarkers.
Availability of validated animal disease models a. Problem: There is a critical need to develop animal disease models that mimic field infections using statistically significant numbers of animals per group and standardized challenge inocula. Also critical is the need to share challenge inoculums from a single source to reduce experimental variations.
b. Potential Solutions: Define validated disease challenge models with respect to challenge dose, challenge inoculum that are similar to the field situation with respect to virulence and pathogen genomic sequence, and designate resource centres specialized in given disease models to share information through public websites.
c. Recommendations:
• Define the acceptable variability in the models and share expertise and knowhow in the conduct of challenges.
• Identify research centres that maintain genetically well-defined animal breeds with different disease phenotypes as a resource for developing animal disease models.
d. Next Steps:
Develop an international working group with disease challenge expertise for each disease model that can interact closely and share information and resources.
Animals with defined disease susceptible/disease resistant phenotypes a. Problem: There is a lack of livestock and poultry breeds with well characterized genotypes and disease phenotypes whose variations can be correlated with innate and acquired immune status of the host.
b. Potential Solutions:
• Identify disease phenotypes important to industry and determine how host and pathogen genetic polymorphisms such as SNPs influence the outcome of host-pathogen interactions and disease resistance phenotypes.
• Increase the genetic analysis ofanimals with characterized animal phenotypes in challenge experiments to build SNP maps that define the influence of genetic polymorphisms on host immune response to pathogens.
c. Recommendations:
• Conduct genetic analyses to investigate how genetic variations of host and pathogens influence disease phenotypes in infection and vaccination studies.
• Identify breeds that vary in phenotypic expression of health traits and open these resources to all scientists conducting research in animal genomics d. Next Steps: 1. Carry out studies that can lead to the identification of potential candidate genes that control host-pathogen interactions. 2. Determine QTL and SNPs of host and pathogens that correlate with disease phenotypes, and carry out host whole genome expression analysis using tissuespecific microarray to identify genes located near QTL that influence important disease parameters. 3. Integrate functional genomics research results in host-pathogen studies to identify potential candidate markers for priority diseases and validate these markers in large population studies using validated animal disease challenge models.
Bioinformatics tools
a. Problem: Animal health research laboratories lack bioinformatics infrastructure: computer hardware, software, and trained scientists in computational biology. There is also a lack of animal and pathogen species-specific genomics and proteomic tools with well-annotated genome databases to predict key immunogenic epitopes in the context of different target species to understand the triggering mechanisms of the protective immune response and to evaluate vaccine-induced immunity for the animal health research community.
b. Potential Solutions:
• Train animal health scientists in computational biology.
• Build bioinformatics infrastructure within animal health research centres.
• Build international animal genome databases.
• Utilize available genomics resources developed in mouse and human systems, and build comparison maps for immune system genes in the target animal species.
• Align international consortia with the aim ofbuilding animal genome databases as well as genome databases for important classes of animal pathogens.
c. Recommendations:
• Build specific databases for each target animal species and pathogen type and establish a systematic programme for training and sharing predictive tools. • Use computational biology and statistical bioinformatics tools to analyze differences between pathogenic and non-pathogenic strains, and differential host response to immunogenic epitopes using genetically disparate inbred lines with well-characterized disease phenotypes.
• Initiate projects for comparative pathogenomics of similar microorganisms in different animal species.
• Integrate genetic, functional genomic, and bioinformatics data in a systems biology approach to understand complex diseases.
d. Next Steps:
1. Establish bioinformatics infrastructure with state-of-the-art genomic tools and resources that can integrate genotype, phenotype and functional genomics data for each animal species and priority diseases.
2. Establish core centres with trained computational biologists for each animal species and establish a user-friendly bioinformatics database that other scientists can access for analysis of functional genomics data. 3. Establish core centres for classes of priority animal pathogens and build user friendly annotated genome databases. Whenever possible, align animal pathogen databases with human pathogens databases or the same class; e.g., apicomplexa parasites.
Identification of genes that are involved in the activation/repression of key regulatory pathways
a. Problem: There is a need to identify molecular pathways of host and pathogens that are involved in transmission, survival, virulence, innate and adaptive immune responses, and protective immune response to natural infection and vaccination. The ultimate goal is the need to identify the 'operational limits'in the genomic 'imbalance' associated with current genetic selection.
b. Potential Solutions:
• We need a more comprehensive approach for using functional genomics to lead us to polymorphisms that will be useful for predicting genetic merit for animal health traits. One potential approach is to use QTL studies to identify small sets of animals that are expected to differ only in whether they have favorable or unfavorable genotypes at the QTL. Use highly parallel gene expression technology (microarrays or SAGE) to determine differences in expression in relevant tissue samples that are due to the QTL. Develop RT-PCR or other similar assays for the transcripts that are most highly related to QTL genotype in the small sample. Run these RT-PCR assays on the entire QTL population and redo the QTL scan. The expression data are expected to be much higher in heritability, and therefore, a much better data set for QTL detection, than direct disease data. This QTL scan should provide much better information for locating the position of the QTL and establishing relationships between haplotypes and disease resistance that should holdup across multiple breeds.
• Develop genome-wide high throughput transcriptional profiling systems to study host-pathogen interactions and identify key candidate host and microbial genes that are associated with infection, pathogenicity, antigenic variation and host range specificity.
• Invest more resources and time into the interactomics and metabolomics area.
c. Recommendations:
• A comprehensive approach to using functional genomics to discover polymorphisms for predicting genetic merit will require significant resources and could be greatly enhanced by effective collaborations between institutions that have expertise in functional genomics, those that have appropriate populations for QTL detection and validation, and those with resources and expertise in phenotyping animal health traits. Build key regulatory pathways relevant to each disease trait using well annotated genome and protein databases for each species.
• Identify host and pathogen genes critical for host-pathogen interactions; e.g., protective immunity.
• Validate the role of key host and pathogen genes important in disease resistance using gene knock-out and transgenic animal models.
d. Next Steps:
1. Funding agencies should consider funding longer-term projects to support the infrastructure needed to develop animal populations with desirable health traits, the extensive phenotyping of these populations, and genome-wide genotyping of these populations. 2. Identify centres with a bioinformatics capability for each animal species and pathogen and establish genomics databases for key immune and metabolic pathways related to host-pathogen interaction. 3. Develop and support proteomics tools to identify key host molecules important in protective immune mechanisms. 4. Integrate functional genomics databases with host-pathogen studies to identify signature regulatory pathways for target diseases.
Development and availability of reagents to study gene function a. Problem:
There is a need to develop a full set of specific research reagents for the key gene products involved in immune functions.
b. Potential solutions:
• Identify research centres with the capability to develop immune reagents and specific knock-out tools (e.g., siRNAs).
• Expand existing research projects on the development of immunological reagents for different animal species.
c. Recommendations:
• Establish an international consortium to advance and enable the development of reagents to study gene function of animal species. • Build and support formal working groups such as the US Veterinary Immune Reagent Network and align with other working groups for priority animal species that can interact closely to identify, develop and commercialize a complete list of immune reagents (and other tools) identified and validated by the scientific community.
• Increase and foster communication among scientists to identify new technologies and enhance collaborations to maximize the impact of available resources in animal genomics.
d. Next Steps:
1. Using national and international immunology meetings, organize a regular workshop to update the progress of veterinary reagent development efforts and establish a publicly accessible database to list all available immune reagents. 2. Designate commercial partners who can organize marketing of recombinant proteins and antibodies for immunology research and establish national repositories to store DNA, recombinant proteins and antibodies for easy access by the animal health research community.
Increase fundin opportunities for basic immunology and reagent de clopmcnt research by governmental granting agencies, e.g. the USDA, DHS, NIH, NSF, BBSRC, and the European Commission. Consider profiling the microbial environment, which is now possible with high throughput sequencing (e.g., metagenomics). In the best case scenario, th IS would identify pathogenic organisms or interactions that promote disease.
fliscoierr othiomarkers a. Problem: It is paramount that the animal health research community has access to measurable biomarkers linked to disease susceptibility, disease resistance, and mechanisms of protective immunity.
b. Potential Solutions:
Conduct biomarker discovery studies with 'standardized' validated animal models that have well defined phenotypes.
c. Recommendations:
Increase the use ofproteomics and microarray technologies in biomarker discovery studies and implement the rational use of proteomics data to develop specific biochips/protein chips for genomics research. 
Translating genomic information to tools for controlling diseases
Genomic tools are providing new opportunities for understanding genetic diversity, the genetic variation associated with diseases processes, and host-pathogen interactions. The scientific information generated from the use of these tools in animal health research will enable the rational design of highly effective diagnostics, vaccines, drugs, biotherapeutics, and animals resistant to diseases.
The main issues: 1. Using animal genomes to understand genetic diversity and inform best management practices to improve animal health and animal production systems worldwide; 2. Easy to use diagnostic platforms for genetic tests, forensic veterinary medicine, and traceability; 3. Selection of animals with disease susceptible and resistant traits; 4. Application of genome-enabled technologies in drug and vaccine discovery, including transgenic animals that are resistant to disease and the selection of animals that respond effectively to drugs and vaccines.
Using animal genomes to understand genetic diversity and inform best management practices to improve animal health and animal production systems a. Problem: There is a critical need to preserve animal genetic diversity and to understand the role ofgenetic variations on host responses to diseases, drug treatments, and vaccination.
b. Potential Solutions:
• Use genome wide genetic markers and novel methods to actively manage animal biodiversity.
• Study the dynamics of specific and general response to disease challenges, especially innate immunity.
• Evaluate animal disease models that try and replicate 'real world' disease complexes, such as the polymicrobial infections associated with the bovine respiratory disease complex.
• Establish general guidelines for using genomic tools in drug and vaccine clinical trials to identify the genotype of study animals and their response to the challenge and/or test treatment.
c. Recommendations:
• Support initiatives that use animal genomic innovations to assess and manage domestic and wildlife animal genetic diversity.
• Support studies that will investigate the use ofgenome-wide markers to monitor and prevent the loss of important non-selected components of animal genomes.
• Integrate genetic profiling in the development of disease models for drug and vaccine discovery research.
• Integrate genomics tools in drug and vaccine clinical trials.
d. Next Steps:
1. Make preserving animal genetic diversity a priority. 2. Support comparative genomics studies, within and across animal species, which integrate host and pathogen genetic variations.
Easy to use diagnostic platforms for genetic tests, forensic veterinary medicine and traceability
a. Problem: There is a lack of rapid, robust, accurate and cost effective genetic tests to use in analyzing disease outbreaks for both the disease agent and the host.
b. Potential Solutions:
• Develop molecular diagnostics for genotyping hosts and pathogens.
• Develop diagnostic platforms to predict new and emerging high-virulence pathogenic strains and the expected susceptible animal populations.
• Develop molecular diagnostics to facilitate the traceability of animals with desired or undesired health traits.
c. Recommendations:
• Develop better description and characterization of genetic variations in target host populations and the pathogens that pose the greatest threats to these populations.
• Support the development of diagnostics to detect gene expression signatures that can predict the emergence of new pathogens and the identification of susceptible animal populations.
• Support research that will lead to the discovery of rapid and user-friendly diagnostics for the traceability of animals. programmes. This will require strategic collaborations with commercial breeding companies.
b. Potential Solutions:
• Establish collaborations from an early stage using animals in well structured populations with good records and already well characterized phenotypes.
• Animal challenge models must be commercially realistic and include polymicrobial /combined disease challenges.
• Establish correlated responses to selection for any marker.
c. Recommendations:
• Support research programmes that include collaborations between public research institutions and commercial breeding companies.
• Integrate disease resistance traits with existing multi-trait selection programmes.
• Use data from large scale disease exposures, especially in sib-test situations.
• Use case control studies in commercial environments.
d. Next Steps:
1. Improve the evaluation ofmarker gene effects in multi-trait selection programmes. 2. Assess and monitor the impact of genomic-based marker selection. 3. Improve statistical analyses of case control studies.
Application of genome-enabled technologies in drug and vaccine discovery, including transgenic animals that are resistant to disease and the selection of animals that respond effectively to drugs and vaccines.
a. Problem: The application of animal genome-enabled tools will demand fundamental changes in the approaches used to discover and develop animal drugs and vaccines, including their delivery and application in disease control programmes. One of the main challenges is the total absence of regulatory guidelines for the applications of these new technologies, including transgenic animals. The ability to design drugs and vaccines for genetically defined animal populations will require additional planning. For instance, in the area of vaccines, there is a lack of established 'vaccine profiles' to identify specifically what a vaccine is expected to achieve (e.g., efficacy with one dose, mass vaccination capability, prevent disease transmission, etc.) for specific diseases in individual animals and targeted commercial populations. Vaccines must not only be designed to achieve the desired vaccine profile but must also anticipate the genetic variations of the host and pathogens to enable predicted outcomes in vaccination campaigns and the selection ofgood responders to vaccination.
Collaborations between the public and private sectors a. Problem: Animal health is a very broad area with different diseases affecting different sectors, species, and regions. There is a lack of understanding of the opportunities for new approaches and in particular what is required for progress. There is a critical dearth of funding for animal health research and bias against nonhypothesis led approaches.
b. Potential Solutions:
• Establish priorities for research-specific diseases, general 'robustness.' • Establish funding mechanisms that enable researchers to work with producers and provide access to large numbers of relevant animals.
• Plan to exploit disease problems at the commercial level including 'SWAT teams' to collect phenotypic information and appropriate samples (including environmental data).
c. Recommendations:
• Establish a cost/benefit analysis (the business case) of research approaches in order to support priorities and build funding initiatives.
• Develop integrated approaches that include the development ofsample repositories and databases that support research networks • Support the funding of innovations in animal genomics research specifically designed to solve problems in animal health d. Next Steps: Build dialogue between researchers, industry, and funding agencies.
Intellectual property and technology transfer to industry
a. Problem: Too many groups are involved in 'protecting' IP before any is developed, inhibiting cooperation or blocking progress. Adversarial approaches to protection predominate. Possible competition between genetic and 'pharma' approaches may reduce investment.
b. Potential Solutions: Seek to develop approaches based on pre-competitive research.
Seek an 'open' shared approach to generating 'next generation' IP. Create 'incubator' opportunities to take results to application. c. Recommendations: Seek to develop a culture that seeks faster application and focuses on protection of 'solutions' rather than concepts.
d. Next Steps:
Continue to organize and provide incentives for public/private partnerships.
Impact on veterinary education and animal and poultry science a. Problem: There is little dialogue between veterinarians and animal and poultry scientists particularly in relation to the genetics of animal health. The focus tends to be on disease challenge or in vitro approaches with limited numbers of animals or genetic variation.
b. Potential Solutions:
• Seek to stimulate multidisciplinary teaching across schools.
• Seek to stimulate joint research across disciplines.
• Seek to stimulate 'host-centered' approaches.
c. Recommendations: Develop more 'epidemiological'approaches to the genetics of animal health and integrate them into veterinary and animal science educational programmes. Bring experts on infectious diseases together with genomics/genetics groups addressing animal health.
Foster cross-fertilization between veterinary and animal science university programmes.
Contributions ofveterinary practitioners, animal health professionals, and animal agriculture allied industries a. Problem: There is a lack of a unified vision on the opportunity of genomics for animal health, a lack of understanding of actions required to investigate the genetics of animal health, and poor definition of new tools required to undertake the required research.
b. Potential Solutions:
• Develop a strategic vision for animal genomics for animal health setting out the roles of each group of industry professionals.
• Create a communication programme to stimulate the interest of, and dialogue between, these groups.
• Focus on solutions that work at the population level.
c. Recommendations:
• Establish a mechanism to assess the contribution ofdifferent genomic approaches (e.g., marker discovery, gene profiling, genetic variations associated with vaccine responses) to improving animal health.
• Establish demonstration projects to deliver examples of the value of genomics approaches.
d. Next Steps:
Organize strategic workshops to seek stakeholder input and support.
Support from regulatory agencies to enable these new technologies a. Problem: The regulatory environment for 'gene-based' technologies, e.g., genetic modification, cloning, RNA interference, and transgenics, is unclear and inhibits research (as well as commercialization).
b. Potential Solutions:
• Develop a science-based approach to 'technical' aspects of regulation.
• Utilize 'participatory' approaches to stimulating public debate and inform the regulatory process.
• I)c\ clop a regulatory vtein to deal with iaLics ol public acceptability in parallel with the technical aspects.
• Benchmark other industries in relation to 'licensing' of new and/or advanced technology.
c. Recommendations: Establish a regulatory framework that enables the potential benefits ofgenome-enabled technologies to be established and provides a clear path for registering products derived from biotechnology.
d. Next Steps:
OlE to seek to establish leadership in harmonizing approaches to the regulation of gene-based technology applied to animal health.
CONCLUSION
The availability ofnew animal genomics tools provides extraordinary opportunities for solving some ofthe most pressing and difficult problems in animal health research. Animal genomics also provides new innovative approaches for controlling diseases affecting domestic animals and wildlife. Quantitative genetics, functional genomics, translating genomics information into tools for controlling diseases, and integrating stakeholder support were identified as four priority areas for animal health research. Investing in basic research was also identified as critical for the sustainability and success ofanimal genomics research in animal health. The application ofnew genomeenabled technologies in animal health research has the potential of significantly improving the health and welfare of animals, resulting in improved efficiency, sustainability, biosecurity, and the protection of animals worldwide. This report provides a roadmap for moving forward by providing recommendations and concrete steps to achieve the impact that animal genomics offers animal health research.
